The Types segment classifies testing methodologies into ELISA‑based assays, Rapid Fluorescent Focus Inhibition Test (RFFIT), Virus Neutralization Tests (VNT), and emerging multiplex platforms. ELISA assays, the most widely adopted due to scalability and cost‑effectiveness, capture approximately 50% of service volume, especially in high‑throughput settings. RFFIT, valued for its sensitivity in measuring functional neutralizing antibodies, accounts for 25% and is preferred in clinical trial protocols where precise titration is critical. VNT, though labor‑intensive, provides gold‑standard confirmation and contributes 15% of the market, primarily for regulatory submissions. Multiplex assays, integrating multiple antigens in a single run, represent a nascent but rapidly growing niche at 10%, driven by demand for comprehensive immunoprofiling. This typology clarifies how each testing format supports distinct client needs, reinforcing the overall market taxonomy and guiding strategic investments in technology development.